PRO^a	PBO^c	Tofacitinib	Tofacitinib	Adalimumab
% of pts reporting improvements ≥MCID^b	n=46	5 mg BID	10 mg BID	40 mg Q2W
[MCID values]		n=127	n=134	n=125
PtGA	-12.48	-28.63***	-29.02***	-26.00**
% pts reporting ≥MCID [-10]	62.37	70.11	72.38	70.56
Pain (VAS)	-16.34	-30.68***	-31.38***	-27.25**
% pts reporting ≥MCID [-10]	64.52	72.41	74.59	69.27
Physical function (HAQ-DI)	-0.33	-0.66***	-0.68***	-0.57**
% pts reporting ≥MCID [-22]	56.99	71.84*	77.35**	74.44*
HR-QoL (SF-36)
Physical Component Score	4.72	8.52**	8.81***	7.25*
% pts reporting ≥MCID [2.5]	72.04	68.21	70.00	71.51
Mental Component Score	0.89	5.51**	6.00***	3.93*
% pts reporting ≥MCID [2.5]	30.11	58.38***	59.44***	51.96**
Fatigue (FACIT-F)	1.92	6.99***	7.85***	6.47**
% pts reporting ≥MCID [4]	45.65	57.23	67.40**	55.56
Sleep (MOS Sleep Scale; overall sleep)	-4.14	-12.47**	-12.13**	-10.26*

^aFull analysis set, longitudinal model; ^bFull analysis set, no imputation; ^cPBO patients with ≥20% improvement in TJC and SJC at Month 3 who were not advanced to tofacitinib until Month 6; CI, confidence interval; MCID, minimum clinically important difference, *p<0.05, **p<0.001, ***p<0.0001 vs PBO.